文献速递免疫规划

DebioJect™皮内狂犬病免疫的安全性、耐受性和有效性

Safety, tolerability and efficacy of intradermal rabies immunization with DebioJect™.
PubMed 文献 · Vaccine · 2017-01-01

单中心研究将66名18至50岁健康志愿者随机分为三组,分别采用DebioJect™皮内注射(IDJ)、经典针头皮内注射(IDS,即Mantoux法)和经典针头肌内注射(IM)接种狂犬病疫苗。结果显示DebioJect™安全可靠有效,IDJ较IDS和IM在针头插入和疫苗注射时疼痛显著降低,所有参与者均被认为获得狂犬病免疫,三种途径体液免疫应答无显著差异。

要点

  • DebioJect™皮内注射较经典针头皮内和肌内注射在针头插入和疫苗注射时疼痛显著降低。
  • IDJ与IDS局部反应性症状相似,仅IDJ注射生理盐水后30分钟红斑更多。
  • 研究结束时所有参与者均被认为获得狂犬病免疫,三种途径体液免疫应答无显著差异。

核心结论

  • DebioJect™是一种安全、可靠且有效的装置,所有参与者均被认为获得狂犬病免疫,三种途径体液免疫应答无显著差异。

研究设计与样本

  • 单中心研究,66名18至50岁健康志愿者随机分为IDJ、IDS(Mantoux法)和IM三组,于D0、D7和D28接种狂犬病疫苗和生理盐水,两种皮内途径抗原剂量为IM剂量的1/5。

主要发现

  • IDJ较IDS和IM在针头插入和疫苗注射时疼痛显著降低。
  • IDJ与IDS在注射疫苗或生理盐水后所有局部反应性症状(疼痛、红斑和瘙痒)相似,仅IDJ注射生理盐水后30分钟红斑更多。
  • 无系统性征集性不良事件被认为与DebioJect™和经典针头相关,无不良事件被认为与DebioJect™相关,研究期间未报告严重不良事件。
  • 研究结束时所有参与者均被认为获得狂犬病免疫,三种途径体液免疫应答无显著差异。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In a single-center study, 66 healthy volunteers aged between 18 and 50years were randomized to be immunized against rabies with three different injection routes: intradermal with DebioJect™ (IDJ), standard intradermal with classical needle (IDS), also called Mantoux method, and intramuscular with classical needle (IM). "Vaccin rabique Pasteur®" and saline solution (NaCl 0.9%) were administered at D0, D7 and D28. Antigen doses for both intradermal routes were 1/5 of the dose for IM. Tolerability, safety and induced immunogenicity of IDJ were compared to IDS and IM routes. Pain was evaluated at needle insertion and at product injection for all vaccination visits. Solicited Adverse Event (SolAE) and local reactogenicity symptoms including pain, redness and pruritus were recorded daily following each vaccination visit. Adverse events (AE) were recorded over the whole duration of the study. Humoral immune response was measured by assessing the rabies virus neutralizing antibody (VNA) titers using Rapid Fluorescent Focus Inhibition Test (RFFIT). Results demonstrated that the DebioJect™ is a safe, reliable and efficient device. Significant decreases of pain at needle insertion and at vaccine injection were reported with IDJ compared to IDS and IM. All local reactogenicity symptoms (pain, redness and pruritus) after injection with either vaccine or saline solution, were similar for IDJ and IDS, except that IDJ injection induced more redness 30min after saline solution. No systemic SolAE was deemed related to DebioJect™ and classical needles. No AE was deemed related to DebioJect™. No Serious Adverse Event (SAE) was reported during the study. At the end of the study all participants were considered immunized against rabies and no significant difference in humoral response was observed between the 3 studied routes.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Vescovo P, Rettby N, Ramaniraka N, et al. Safety, tolerability and efficacy of intradermal rabies immunization with DebioJect™. Vaccine. 2017. PMID: 28317660. doi:10.1016/j.vaccine.2016.09.069

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。